The Latin America Veterinary Biologics Market was valued at $137.55 Million in 2025 and projected to reach to $168.46 Million by 2030, representing a compound annual growth rate of 4.1%. Latin America's veterinary biologics market is positioned for steady growth driven by intensifying livestock operations and rising animal health awareness.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Latin America's veterinary biologics market is expanding at a CAGR of 4.1%, growing from USD 137.55 million in 2025 to USD 168.46 million by 2030, outpacing several developed regions despite being below the global average of 5.2%.
Rising livestock production across Latin America, particularly in Brazil, Mexico, and Argentina, is driving demand for veterinary biologics including vaccines, immunologics, and diagnostic biologics to ensure herd health and productivity.
Increasing pet ownership and urbanization in Latin American countries are creating new market opportunities for companion animal biologics, with growing consumer spending on pet healthcare and preventive treatments.
Brazil and Mexico represent the largest markets in Latin America, collectively accounting for a significant portion of regional demand, while Rest of Latin America shows emerging growth potential in veterinary biologics adoption.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | CANINE (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 5.2% from 2025 to 2030 |
| Largest Segment | INJECTABLE ROUTE OF ADMINISTRATION (Route Of Administration) |
| Market Size Base Year (Billions) | ~USD 2.72 (2025) |
| Revenue Forecast (Billions) | ~USD 3.51 (2030) |
| Segments Covered | Product Type, Animal Type, Type, Route Of Administration, Application, End User |
6 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| IDEXX | United States | Public Company | Companion Animal Group (in-clinic diagnostics, reference labs, services, software),Water Quality Products,Livestock, Poultry and Dairy (including related diagnostics), |
| ELANCO | United States | Public Company | Companion animal parasiticides (Seresto, K-9 Advantage, Advantix, Advocate, Credelio Family, Interceptor Plus, Drontal),Companion animal vaccines and therapeutics (Galliprant, Atopica, Milbemax, Onsior, Tru Family),Farm animal feed additives and productivity enhancers (Rumensin, Experior, Hemicell, Surmax, Pulmotil), |
| MERCK & CO., INC. | United States | Public Company | Oncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations),Vaccines (Gardasil, pediatric and adult vaccines including Vaxneuvance, Capvaxive),Cardiovascular, pulmonary hypertension and specialty (Winrevair, Adempas/Verquvo, Ohtuvayre, others), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| NEOGEN CORPORATION | United States | Public Company | Food Safety diagnostics, media, and sanitation,Animal Safety instruments, care products, and biosecurity,Genomics services for livestock and companion animals, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Instruments and Systems,Life Science Reagents and Consumables, |
| IMMUCELL CORPORATION | United States | Public Company | First Defense (core scours prevention),Tri-Shield First Defense,Dual-Force First Defense and related formulations, |
IDEXX is a public company founded in 1983 and headquartered in the United States, employing 11,000 people.
Elanco is a public company founded in 1954 in the United States with 9,650 employees.
Merck & Co., Inc. is a public pharmaceutical company founded in 1891 and based in the United States, with 74,000 employees.
Thermo Fisher Scientific Inc. is a public company founded in 1956 in the United States and employs 125,000 people.
Neogen Corporation is a public company founded in 1981 in the United States with 2,974 employees.
Bio-Rad Laboratories, Inc. is a public company founded in 1952 in the United States and employs 7,450 people.
ImmuCell Corporation is a public company founded in 1982 in the United States with 73 employees.
| Country | 2025 size (native) |
|---|---|
| Brazil | USD 42.03 Million |
| Mexico | USD 25.92 Million |
| Rest Of Latin America | USD 18.88 Million |
In 2025, Latin America's veterinary biologics market is valued at USD 137.55 million and is expected to grow to USD 168.46 million by 2030.
Latin America's veterinary biologics market is projected to grow at a compound annual growth rate (CAGR) of 4.1% from 2025 to 2030.
Latin America's market growth is driven by increased livestock production, rising pet ownership, expanding disease prevention programs, and strengthening regulatory frameworks across the region.
In Latin America, vaccines and immunological products represent the largest segments, serving both production animals and companion animal markets.
Latin America's 4.1% CAGR is slightly lower than the global 5.2% CAGR, reflecting a more moderate but stable growth trajectory within the region.
This study extensively used both primary and secondary sources. The research process examined various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, market dynamics, and strategies of major players.
This research involved the use of comprehensive secondary sources, including directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was employed to gather information for an extensive, technical, market-focused, and commercial analysis of the veterinary biologics market. It also helped obtain crucial details about key players, market classification, and segmentation based on industry trends at the most detailed levels, as well as significant developments related to market and technology perspectives. Additionally, a database of major industry leaders was created using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources from the supply side include project managers, sales managers, marketing managers, business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary biologics market. Primary sources from the demand side consist of professionals from veterinary hospitals and clinics, diagnostic labs, academic and research institutes, and pet owners.
A breakdown of the primary respondents is provided below:
Note 1: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 2: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Note 3: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.
Source: MarketsandMarkets Analysis
To know about the assumptions considered for the study, download the pdf brochure
The total size of the veterinary biologics market was determined through data triangulation from three different approaches, as outlined below. After each approach, a weighted average was calculated based on the level of assumptions used in each method.

After defining the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown methods were used where applicable to complete the overall market analysis and determine accurate statistics for all segments and subsegments. The following figure illustrates the market validation, source structure, and data triangulation approach used in the market analysis process.
The veterinary biologics market includes all USDA-regulated biologic products, such as monoclonal antibodies, immunoglobulins, immunomodulators, and diagnostic kits, which are used for the prevention, diagnosis, or treatment of animal diseases. These products serve companion animals, livestock, and poultry across veterinary clinics, hospitals, diagnostic labs, and farm or herd settings, enabling veterinarians and animal health professionals to provide targeted immune-based interventions and rapid diagnostic testing. This allows infected animals to be identified quickly for faster treatment, containment, or herd management decisions.
Full forecast, segment splits, and company analysis for all Veterinary Biologics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report